AGIOS PHARMACEUTICALS, INC. Accounts and Other Receivables, Net, Current
AGIOS PHARMACEUTICALS, INC. (AGIO) had Accounts and Other Receivables, Net, Current of $0 as of 2022-12-31, per its 10-K filed 2023-02-23.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:AccountsAndOtherReceivablesNetCurrent · last filed 2023-02-23
- 2022-12-31: Accounts and Other Receivables, Net, Current $0.00.
- 2021-12-31: Accounts and Other Receivables, Net, Current $4.38M.
- 2020-12-31: Accounts and Other Receivables, Net, Current $0.00.
- 2017-12-31: Accounts and Other Receivables, Net, Current $169.00K.
| Period end | Accounts and Other Receivables, Net, Current |
|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-02-23 |
| 2021-12-31 | $4.38M 10-K · filed 2023-02-23 |
| 2020-12-31 | $0.00 10-K · filed 2022-02-24 |
| 2017-12-31 | $169.00K 10-K · filed 2018-02-14 |
| 2017-09-30 | $859.00K 10-Q · filed 2017-11-01 |
| 2017-06-30 | $779.00K 10-Q · filed 2017-08-08 |
| 2017-03-31 | $3.45M 10-Q · filed 2017-05-04 |
| 2016-12-31 | $3.43M 10-K · filed 2018-02-14 |
| 2016-09-30 | $3.39M 10-Q · filed 2016-11-03 |
| 2016-06-30 | $2.01M 10-Q · filed 2016-08-08 |
| 2016-03-31 | $571.00K 10-Q · filed 2016-05-09 |
| 2015-12-31 | $3.37M 10-K · filed 2017-02-16 |
| 2015-09-30 | $2.99M 10-Q · filed 2015-11-06 |
| 2015-06-30 | $5.28M 10-Q · filed 2015-08-07 |
| 2015-03-31 | $6.91M 10-Q · filed 2015-05-11 |
| 2014-12-31 | $2.33M 10-K · filed 2016-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |